Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H3 | Q13133 | 6/20 | 0.42 |
| ▸ | ESR1 | P03372 | 1/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.42 |
| ▸ | RORC | P51449 | 11/20 | 0.40 |
| ▸ | NR1I2 | O75469 | 3/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | KIF11 | P52732 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3625724 | 0.80 | GAA (0.42) | NR1H3RORCNR1I2NR1H2GAA | |
| SCHEMBL15888360 | 0.79 | ESR1 (0.51) | ESR1ESR2KIF11 | |
| SCHEMBL26613441 | 0.79 | ESR1 (0.51) | ESR1ESR2KIF11 | |
| SCHEMBL29746449 | 0.79 | ESR1 (0.51) | ESR1ESR2KIF11 | |
| SCHEMBL29746091 | 0.77 | ESR1 (0.52) | ESR1ESR2GAAKIF11 | |
| SCHEMBL26613367 | 0.77 | ESR1 (0.52) | ESR1ESR2GAAKIF11 | |
| SCHEMBL3623833 | 0.76 | MEN1 (0.57) | NR1H3RORCNR1I2NR1H2 | |
| SCHEMBL11472931 | 0.74 | AR (0.42) | NR1H3ESR1ESR2RORCNR1I2 | |
| SCHEMBL618869 | 0.74 | MEN1 (0.44) | ESR1ESR2GRIN2BGAA | |
| SCHEMBL6490339 | 0.72 | GAA (0.62) | NR1H3RORCNR1I2NR1H2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1951676-B1 | N-ACYL BENZAZEPINE DERIVATIVES AS LXR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2013-07-17 | — | — | EP | disclosed |
| US-7741317-B2 | LXR modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-06-22 | — | — | US | disclosed |
| US-20070093470-A1 | LXR modulators | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093470-A1 | LXR modulators | NR1H2, NR1H3, RXRB | NR1H3 2/4885ESR1 52/4885ESR2 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.